Treatment of Acute Non-Cardioembolic TIA with ABCD2 Score of 4 or More
Patients presenting with acute non-cardioembolic transient ischaemic attack and an ABCD2 score of 4 or more represent a high-risk group requiring prompt and specific antiplatelet management to reduce the risk of subsequent stroke.
Acute non-cardioembolic transient ischaemic attack with an ABCD2 score of 4 or more. This threshold identifies patients at elevated short-term risk where early, targeted antiplatelet treatment is indicated.
In this setting, current evidence supports a short-term dual antiplatelet strategy initiated as soon as possible after onset, with a planned transition to single-agent therapy after a defined period. The complete agent selection, dosing sequence, transition timing, and alternative options for specific subgroups are contained in the full structured protocol.
DOI: 10.1177/2396987321992905
In patients with acute non-cardioembolic high risk TIA (ABCD2 score of 4 or more), we recommend short term dual antiplatelet therapy with aspirin and clopidogrel over monotherapy, subsequently followed by monotherapy.
Dual antiplatelet therapy with aspirin and clopidogrel should be started as soon as possible, and ideally within the first twenty-four hours.
Between 10 days and three weeks after starting dual antiplatelet therapy (DAPT) we suggest stopping one of the antiplatelet medications, and thereafter continuing the other antiplatelet as monotherapy based on local protocols and patient preference.
View source ↗